INOSITOL NICOTINATE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Inositol nicotinate is a compound made of niacin (vitamin B3) and inositol. Inositol occurs naturally in the body and can also be made in the laboratory.

Inositol nicotinate is used for blood circulation problems, including a painful response to cold, especially in the fingers and toes (Raynaud syndrome). It is also used for high cholesterol, high blood pressure, and many other conditions, but there is no good scientific evidence to support these uses.

How does it work ?

Inositol nicotinate releases niacin, or vitamin B3, when it is processed by the body. Niacin can widen blood vessels, lower blood levels of fats such as cholesterol, and break up a protein needed for the clotting of blood.

Uses & Effectiveness

Possibly Effective for

Painful response to cold especially in the fingers and toes (Raynaud syndrome). Some research shows that taking a specific product of inositol nicotinate (Hexopal) by mouth for several weeks modestly improves symptoms of Raynaud syndrome.

Insufficient Evidence for

High levels of cholesterol or other fats (lipids) in the blood (hyperlipidemia). The effectiveness of inositol nicotinate for treating high cholesterol is unclear. Some research shows that inositol nicotinate can decrease cholesterol levels. But other research shows that inositol nicotinate does not have an effect.
Leg pain during exercise due to poor blood flow (intermittent claudication). The effectiveness of inositol nicotinate for treating intermittent claudication is unclear. Some research shows that taking a specific inositol nicotinate product (Hexopal) by mouth for up to 3 months improves walking distance and reduces symptoms. But other research does not show this effect.
Blood disorders of the brain.
Migraine headache.
Hardened skin (scleroderma).
Insomnia.
High blood pressure.
A disorder that causes leg discomfort and an irresistible urge to move the legs (restless legs syndrome or RLS).
Acne.
Skin inflammation.
Inflammation of the tongue (exfoliative glossitis).
Psoriasis.
Schizophrenia.
Other conditions.

More evidence is needed to rate the effectiveness of inositol nicotinate for these uses.

Side Effects

When taken by mouth: Inositol nicotinate is POSSIBLY SAFE for most people. It can cause some side effects such as stomach upset, intestinal gas, and nausea. It might also cause liver damage like other niacin products in some people.

Some inositol nicotinate products are promoted as "no-flush" niacin because some people think they don't cause as much flushing as regular niacin. But this possible benefit has not been proven in research studies.

Special Precautions & Warnings:

Pregnancy and breast-feeding: There isn't enough reliable information to know if inositol nicotinate is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Allergies: Inositol nicotinate is changed to niacin in the body. Niacin might make allergies worse by releasing histamine. This is the chemical that triggers allergy symptoms.

Chest pain (angina): Inositol nicotinate is changed to niacin in the body. Niacin should be used cautiously in people with angina.

Bleeding disorder: Inositol nicotinate might slow blood clotting. In theory, inositol nicotinate might increase the risk of bleeding and make bleeding disorders worse.

Diabetes: Inositol nicotinate is changed to niacin in the body. Niacin might increase blood sugar. People with diabetes who take inositol nicotinate or niacin should check their blood sugar carefully.

Gallbladder disease: Inositol nicotinate is changed to niacin in the body. Niacin might make gallbladder problems worse. Use with caution.

Gout: Inositol nicotinate is changed to niacin in the body. Large amounts of niacin might trigger gout. Use with caution.

Low blood pressure: Inositol nicotinate is changed to niacin in the body. Niacin can cause low blood pressure. Use with caution.

Kidney disease: Inositol nicotinate is changed to niacin in the body. Niacin might accumulate in people with kidney disease and make their condition worse. Don't use inositol nicotinate if you have kidney problems.

Liver disease: Inositol nicotinate is changed to niacin in the body. Niacin can cause liver damage. Don't use inositol nicotinate if you have liver disease.

Sensitivity to niacin: Inositol nicotinate is changed to niacin in the body. If you are sensitive to niacin, don't use inositol nicotinate.

Stomach ulcers: Inositol nicotinate is changed to niacin in the body. Large amounts of niacin might make peptic ulcer disease worse. Don't use inositol nicotinate if you have ulcers.

Surgery: Inositol nicotinate might slow blood clotting. There is some concern that it might increase the risk of bleeding during and after surgery. Stop taking inositol nicotinate at least 2 weeks before a scheduled surgery.

Fatty deposits around tendons (tendon xanthomas): Inositol nicotinate is changed to niacin in the body. Niacin might increase the risk of infections in xanthomas.

Thyroid disorders: Inositol nicotinate is changed to niacin in the body. Niacin might lower blood levels of thyroxine, a hormone produced by the thyroid gland. This might worsen symptoms of certain thyroid disorders.

Special Precautions and Warnings

Special Precautions & Warnings:

Interactions

Moderate Interaction

Be cautious with this combination

Medications for diabetes (Antidiabetes drugs) interacts with INOSITOL NICOTINATE
Long-term use of inositol nicotinate might increase blood sugar. Diabetes medications are used to lower blood sugar. By increasing blood sugar, inositol nicotinate might decrease the effectiveness of diabetes medications. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.

Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with INOSITOL NICOTINATE
Inositol nicotinate might slow blood clotting. Taking inositol nicotinate along with medications that also slow clotting might increase the chances of bruising and bleeding.

Some medications that slow blood clotting include aspirin, clopidogrel (Plavix), diclofenac (Voltaren, Cataflam, others), ibuprofen (Advil, Motrin, others), naproxen (Anaprox, Naprosyn, others), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, warfarin (Coumadin), and others.
Medications used for lowering cholesterol (Statins) interacts with INOSITOL NICOTINATE
Inositol nicotinate is changed in the body to niacin. Niacin can affect the muscles. Some medication used for lowering cholesterol can also affect the muscles. Taking niacin along with some medications used for lowering high cholesterol might increase the risk of muscle problems.

Some medications used for high cholesterol include cerivastatin (Baycol), atorvastatin (Lipitor), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), and others.
Nicotine patch (Nicoderm) interacts with INOSITOL NICOTINATE
Inositol nicotinate is broken down in the body to niacin. Niacin can sometimes cause flushing and dizziness. Nicotine patches can also cause flushing and dizziness. Taking inositol nicotinate and using a nicotine patch may increase the risk of flushing and dizziness.

Dosing

The following doses have been studied in scientific research:

BY MOUTH:

General: Some dietary supplement products might not list inositol nicotinate separately on the label. Instead, it might be listed under niacin. Niacin is measured in niacin equivalents (NE). 1 mg of inositol nicotinate is the same as 1 mg NE.
Painful response to cold especially in the fingers and toes (Raynaud syndrome): 4 grams daily has been used. It might take several weeks before effects are seen.

View References

REFERENCES:

Lennerz, C., Jilek, C., Semmler, V., Deisenhofer, I., and Kolb, C. Sinus arrest from mad honey disease. Ann Intern Med 2012;157(10):755-756. View abstract.

Li AL, Li SL, Kam KW, Young AL. Randomised assessor-masked trial evaluating topical manuka honey (Optimel) in treatment of meibomian gland dysfunction. Br J Ophthalmol. 2021:bjophthalmol-2020-317506. View abstract.

Liu TM, Luo YW, Tam KW, Lin CC, Huang TW. Prophylactic and therapeutic effects of honey on radiochemotherapy-induced mucositis: a meta-analysis of randomized controlled trials. Support Care Cancer. 2019;27(7):2361-2370. View abstract.

Lubis AS, Herwanto HRY, Rambe AYM, et al. The effect of honey on post-tonsillectomy pain relief: a randomized clinical trial. Braz J Otorhinolaryngol 2021;S1808-8694(21)00164-6. View abstract.

Lund-Nielsen, B., Adamsen, L., Kolmos, H. J., Rørth, M., Tolver, A., and Gottrup, F. The effect of honey-coated bandages compared with silver-coated bandages on treatment of malignant wounds-a randomized study. Wound Repair Regen 2011;19(6):664-670. View abstract.

Münstedt K, Männle H. What is wrong with the meta-analyses on honey and oral mucositis due to cancer therapies? Complement Ther Med. 2020;49:102286. View abstract.

Mahyar A, Ayazi P, Shaftaroni MR, Oveisi S, Dalirani R, Esmaeili S. The effect of adding honey to zinc in the treatment of diarrhea in children. Korean J Fam Med 2022;43(3):188-192. View abstract.

Maiti, P. K., Ray, A., Mitra, T. N., Jana, U., Bhattacharya, J., and Ganguly, S. The effect of honey on mucositis induced by chemoradiation in head and neck cancer. J Indian Med Assoc 2012;110(7):453-456. View abstract.

Malik, K. I., Malik, M. A., and Aslam, A. Honey compared with silver sulphadiazine in the treatment of superficial partial-thickness burns. Int Wound J 2010;7(5):413-417. View abstract.

Mamgain RK, Gupta M, Mamgain P, et al. The efficacy of an ayurvedic preparation of yashtimadhu (Glycyrrhiza glabra) on radiation-induced mucositis in head-and-neck cancer patients: A pilot study. J Cancer Res Ther. 2020;16(3):458-462. View abstract.

Martina SJ, Ramar LAP, Silaban MRI, Luthfi M, Govindan PAP. Antiplatelet Effectivity between Aspirin with Honey on Cardiovascular Disease Based on Bleeding Time Taken on Mice. Open Access Maced J Med Sci. 2019 Oct 14;7(20):3416-3420. View abstract.

Matos D, Serrano P, Menezes Brandão F. A case of allergic contact dermatitis caused by propolis-enriched honey. Contact Dermatitis. 2015 Jan;72(1):59-60. View abstract.

McIntosh, C. D. and Thomson, C. E. Honey dressing versus paraffin tulle gras following toenail surgery. J Wound Care 2006;15(3):133-136. View abstract.

Mirzaei H, Gharehgozlou R, Heydarirad G, et al. Efficacy and safety of Jollab (a saffron-based beverage) on cancer-related fatigue in breast cancer patients: a double-blind randomized clinical trial. Complement Med Res. 2022;29(6):437-45. View abstract.

Misirlioglu A, Eroglu S, Karacaoglan N, et al. Use of honey as an adjunct in the healing of split-thickness skin graft donor site. Dermatol Surg 2003;29:168-72. View abstract.

Mokhtari S, Sanati I, Abdolahy S, Hosseini Z. Evaluation of the effect of honey on the healing of tooth extraction wounds in 4- to 9-year-old children. Niger J Clin Pract. 2019;22(10):1328-1334. View abstract.

Molan PC. The evidence supporting the use of honey as a wound dressing. Int J Lower Extrem Wounds 2006;5:40-54. View abstract.

Moolenaar, M., Poorter, R. L., van der Toorn, P. P., Lenderink, A. W., Poortmans, P., and Egberts, A. C. The effect of honey compared to conventional treatment on healing of radiotherapy-induced skin toxicity in breast cancer patients. Acta Oncol 2006;45(5):623-624. View abstract.

Moore OA, Smith LA, Campbell F, et al. Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med 2001;1:2. View abstract.

Motallebnejad, M., Akram, S., Moghadamnia, A., Moulana, Z., and Omidi, S. The effect of topical application of pure honey on radiation-induced mucositis: a randomized clinical trial. J Contemp Dent Pract 2008;9(3):40-47. View abstract.

Münstedt, K., Hoffmann, S., Hauenschild, A., Bülte, M., von Georgi R., and Hackethal, A. Effect of honey on serum cholesterol and lipid values. J Med Food 2009;12(3):624-628. View abstract.

Naik PP, Mossialos D, Wijk BV, Novakova P, Wagener FADTG, Cremers NAJ. Medical-grade honey outperforms conventional treatments for healing cold sores-a clinical study. Pharmaceuticals (Basel) 2021;14(12):1264. View abstract.

Natarajan S, Williamson D, Grey J, et al. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. J Dermatolog Treat 2001;12:33-6. View abstract.

Nijhuis, W. A., Houwing, R. H., Van der Zwet, W. C., and Jansman, F. G. A randomised trial of honey barrier cream versus zinc oxide ointment. Br J Nurs 2012;21(20):9-3. View abstract.

Nilforoushzadeh, M. A., Jaffary, F., Moradi, S., Derakhshan, R., and Haftbaradaran, E. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. BMC Complement Altern Med 2007;7:13. View abstract.

Nishimura T, Muta H, Hosaka T, Ueda M, Kishida K; Honey and Coughs Study Group of the Society of Ambulatory and General Paediatrics of Japan. Multicentre, randomised study found that honey had no pharmacological effect on nocturnal coughs and sleep quality at 1-5 years of age. Acta Paediatr. 2022;111(11):2157-64. View abstract.

Norman G, Christie J, Liu Z, et al. Antiseptics for burns. Cochrane Database Syst Rev. 2017;7:CD011821. View abstract.

Oduwole O, Meremikwu MM, Oyo-Ita A, Udoh EE. Honey for acute cough in children. Cochrane Database Syst Rev. 2014 Dec 23;12:CD007094. View abstract.

Oduwole O, Udoh EE, Oyo-Ita A, Meremikwu MM. Honey for acute cough in children. Cochrane Database Syst Rev. 2018;4:CD007094. View abstract.

Oguzturk, H., Ciftci, O., Turtay, M. G., and Yumrutepe, S. Complete atrioventricular block caused by mad honey intoxication. Eur Rev Med Pharmacol Sci 2012;16(12):1748-1750. View abstract.

Okeniyi JA, Olubanjo OO, Ogunlesi TA, Oyelami OA. Comparison of healing of incised abscess wounds with honey and EUSOL dressing. J Altern Complement Med 2005;11:511-3. View abstract.

Belch, J. J. and Ho, M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996;52(5):682-695. View abstract.

Cucinotta, D., Silvestrini, C., Mancini, M., Maini, C., and Passeri, M. [Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo]. G.Clin.Med. 1981;62(5):339-350. View abstract.

Domer, V. and Fischer, F. W. The influence of m-inositol hexanicotinate ester on the serum lipids and lipoproteins. Arzneim-Frosch 1961;11:110-113.

Head, A. Treatment of intermittent claudication with inositol nicotinate. Practitioner 1986;230(1411):49-54. View abstract.

Hentzer, E. [Treatment of peripheral arterial insufficiency with inositol nicotinate (Hexanicit)]. Nord.Med. 9-22-1966;76(38):1090-1093. View abstract.

Kiff, R. S. and Quick, C. R. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. Br.J.Clin.Pract. 1988;42(4):141-145. View abstract.

Kramer, K. D., Ghabussi, P., and Hochrein, H. [Antihypertensive combination-therapy with inositol nicotinate in essential hypertension]. Med.Welt. 7-8-1977;28(27):1198-1201. View abstract.

Kramer, K. D., Ghabussi, P., Lehmann, H. U., and Hochrein, H. [Dose-effect comparison of antihypertensive combinations with and without alpha-methyldopa]. MMW.Munch.Med Wochenschr. 4-4-1975;117(14):579-582. View abstract.

O'Hara, J., Jolly, P. N., and Nicol, C. G. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br.J.Clin.Pract. 1988;42(9):377-383. View abstract.

Rhodes, E. L. Fibrinolytic agents in the treatment of necrobiosis lipoidica. Br J Dermatol 1976;95:673-674.

American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. Am J Health Syst Pharm 1997;54:2815-9. View abstract.

Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh). 1977 Jul;41(1):1-10. View abstract.

Anon. Inositol hexaniacinate. Altern Med Rev 1998;3:222-3. View abstract.

Aramwit P, Srisawadwong R, Supasyndh O. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. J Nephrol. 2012 May-Jun;25(3):354-62. View abstract.

Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355-71. View abstract.

Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-93. View abstract.

Brown WV. Niacin for lipid disorders. Indications, effectiveness, and safety. Postgrad Med. 1995 Aug;98(2):185-9, 192-3. View abstract.

Cashin-Hemphill L, Spencer CA, Nicoloff JT, et al. Alterations in serum thyroid hormonal indices with colestipol-niacin therapy. Ann Intern Med. 1987;107(3):324-9. View abstract.

Crouse JR III. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. Coron Artery Dis 1996;7:321-6. View abstract.

Dorner V, Fischer FW. [The influence of m-inositol hexanicotinate ester on the serum lipids and lipoproteins]. Arzneim-Forsch 1961;11:110-13.

Drinka PJ. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin. Mayo Clin Proc. 1992;67(12):1206. View abstract.

Figge HL, Figge J, Souney PF, et al. Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 1988;8:287-94. View abstract.

Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (2000). Washington, DC: National Academy Press, 2000. Available at: https://books.nap.edu/books/0309065542/html/.

Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6. View abstract.

Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52(15):1639-45. View abstract.

Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-85. View abstract.

Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43. View abstract.

He YM, Feng L, Huo DM, Yang ZH, Liao YH. Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol. 2014 Feb;46(2):433-42. View abstract.

Holti G. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res 1979;7:473-83. View abstract.

Hutt V, Wechsler JG, Klor HU, Ditschuneit H. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. Arzneimittelforschung 1983;33:776-9. View abstract.

Ito MK. Advances in the understanding and management of dyslipidemia: using niacin-based therapies. Am J Health-Syst Pharm 2003;60(suppl 2):s15-21. View abstract.

Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10-32. View abstract.

Lakey WC, Greyshock N, Guyton JR. Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants. J Clin Lipidol. 2013 Mar-Apr;7(2):178-81. View abstract.

McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705. View abstract.

Meyers CD, Car MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003;139:996-1002. View abstract.

Niaspan [package insert]. Barcelona, Spain: AbbVie LTD; 2015.

O'Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc. 1992;67(5):465-8. View abstract.

Raising HDL and Niacin Use. Pharmacist's Letter/Prescriber's Letter 2004;20(5):200504.

Reaven P, Witztum JL. Lovastatin, nicotinic acid and rhabdomyolysis (letter). Ann Int Med 1988;109:597-8. View abstract.

Ring EF, Bacon PA. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena. J Int Med Res 1977;5:217-22. View abstract.

Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017 Jun 14;6:CD009744. View abstract.

Schwartzkopff W, Zschiedrich M. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)]. Med Klin. 2-17-1978;73:231-239. View abstract.

Shakir KM, Kroll S, Aprill BS, Drake AJ 3rd, Eisold JF. Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state. Mayo Clin Proc. 1995;70(6):556-8. View abstract.

Sunderland GT, Belch JJ, Sturrock RD, et al. A double-blind, randomized, placebo-controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol 1988;7:46-9. View abstract.

Wilke H, Frahm H. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate]. [Article in German]. Dtsch Med Wochenschr 1976;101:401-5. View abstract.

What Really Works for High Cholesterol

An Injectable for Advanced Cholesterol Care

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

INOSITOL NICOTINATE - Uses, Side Effects, and More

Overview

How does it work ?

Uses & Effectiveness

Possibly Effective for

Insufficient Evidence for

Side Effects

Special Precautions & Warnings:

Special Precautions and Warnings

Special Precautions & Warnings:

Interactions

Moderate Interaction

Medications for diabetes (Antidiabetes drugs) interacts with INOSITOL NICOTINATE

Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs) interacts with INOSITOL NICOTINATE

Medications used for lowering cholesterol (Statins) interacts with INOSITOL NICOTINATE

Nicotine patch (Nicoderm) interacts with INOSITOL NICOTINATE

Dosing

You Might Also Like